Exenatide vs Human Growth Hormone (HGH)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Exenatide

Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).

Full details →

Human Growth Hormone (HGH)

Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.

Full details →

Side-by-Side Comparison

AspectExenatideHuman Growth Hormone (HGH)
MechanismSynthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety.Binds to GH receptors throughout the body, stimulating IGF-1 production in the liver. Promotes protein synthesis, fat metabolism, and cellular regeneration across multiple tissues.
Typical DosageByetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly.Medical: 0.1-0.3mg/kg/week divided into daily doses. Anti-aging: 1-2 IU daily. Performance: 2-6 IU daily, sometimes higher.
AdministrationByetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe.Subcutaneous injection, preferably at night to mimic natural pulsatile release. Rotate injection sites. Store refrigerated.
Side EffectsNausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon).Joint pain, water retention, carpal tunnel syndrome, potential insulin resistance, and acromegaly features with long-term high doses.
Best For

What They Have in Common

Both Exenatide and Human Growth Hormone (HGH) are commonly used for:

Key Differences

Ready to Learn More?